The European Medicines Agency (EMA) will soon assess Novo Nordisk's drug candidate semaglutide as a possible treatment for obesity, Novo Nordisk states in a company announcement on Friday morning, after the pharmaceutical firm has officially filed for approval at the EMA.
Semaglutide for diabetes has been approved as both a tablet and subcutaneous treatment, and Novo Nordisk has filed to have the drug approved as a once-weekly obesity treatment in the latter variant. This is also the case for the US Food and Drug Administration application, which the pharmaceutical company sent 14 days ago.
"It is a milestone for Novo Nordisk but more importantly it represents a new treatment option with the potential to transform the medical management for people living with obesity in Europe," says Novo Nordisk's Executive Vice President and Chief Scientific Officer Mads Krogsgaard Thomsen in the statement.
Novo Nordisk already sells the obesity drug Saxenda, which sold for just under DKK 6bn (USD 989m) in 2019.
Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.
Novo after crucial data from competitor: Welcomes drug R&D Eli Lilly candidate shows weight loss at 11 percent in phase III trial Novo Nordisk submits obesity drug for FDA approval Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo Nordisk Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time" Novo Nordisk plans to make bariatric surgery a thing of the past: The key is not one but two drugs